Nathalie King, PA
Physician Assistant · Racine, WINPI 1528178563
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,172 of the $22,859 with a category attached, or 75.1%. 30 manufacturers reported payments, led by Biogen at 44.0% of the total. Reporting peaked in 2021 at $14,508 and has fallen 95.5% since, to $647 in 2025. Among physician assistant clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $169.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$10K
- AbbVie$8K
- Livanova USA, Inc.$2K
- Acorda Therapeutics, Inc$742
- Novartis$415
- Amneal Pharmaceuticals LLC$222
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$17,17275%
- Travel & lodging$2,20410%
- Food & beverage$3,42315%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 16 | $10,047 |
| AbbVie(2 entities) | 29 | $7,852 |
| Livanova USA, Inc. | 7 | $2,104 |
| Acorda Therapeutics, Inc | 4 | $742 |
| Novartis | 10 | $415 |
| Amneal Pharmaceuticals LLC | 7 | $222 |
| Bristol Myers Squibb | 15 | $205 |
| Lundbeck LLC | 7 | $167 |
| TG Therapeutics, Inc. | 3 | $110 |
| UCB, Inc. | 4 | $101 |
| Biohaven Pharmaceuticals, Inc. | 1 | $94 |
| Pfizer | 4 | $91 |
| Argenx US, Inc. | 3 | $81 |
| Harmony Biosciences LLC | 3 | $77 |
| Acadia Pharmaceuticals Inc | 3 | $68 |
| Johnson & Johnson | 1 | $60 |
| Kyowa Kirin, Inc. | 2 | $55 |
| SK Life Science, Inc. | 2 | $53 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Neurelis, Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $31 |
| Amgen | 1 | $30 |
| Corium, LLC | 1 | $27 |
| Tanabe Pharma America, Inc. | 1 | $26 |
| Merz Pharmaceuticals, LLC | 1 | $25 |
| GE HealthCare | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| Abbott | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,859 in reported general payments places this provider in the 95th percentile of 2,804 physician assistant providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 52 | $463,353 |
| TecfideraDimethyl Fumarate | 19 | $176,353 |
| CopaxoneGlatiramer Acetate | 21 | $156,100 |
| GilenyaFingolimod Hcl | 12 | $141,089 |
| KeppraLevetiracetam | 76 | $128,316 |
| AmpyraDalfampridine | 12 | $123,016 |
| BetaseronInterferon Beta-1b | 13 | $118,661 |
| Lamictal XrLamotrigine | 63 | $109,716 |
| Dimethyl Fumarate | 13 | $105,446 |
| UbrelvyUbrogepant | 62 | $91,462 |
| Glatiramer Acetate | 17 | $89,288 |
| LamictalLamotrigine | 66 | $82,280 |
| Nurtec OdtRimegepant Sulfate | 59 | $73,131 |
| NuplazidPimavanserin Tartrate | 14 | $67,347 |
| TopamaxTopiramate | 33 | $60,780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera | $10,047 | $176,35319 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $31 | $156,10021 claims |
| NovartisGilenya | $415 | $141,08912 claims |
| Acorda Therapeutics, IncAmpyra | $742 | $123,01612 claims |
| AbbVieUbrelvy, Namzaric | $7,852 | $105,35079 claims |
| PfizerNurtec Odt | $91 | $73,13159 claims |
| Acadia Pharmaceuticals IncNuplazid | $68 | $67,34714 claims |
| UCB, Inc.Briviact, Nayzilam | $101 | $56,00959 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,804 physician assistant providers in Wisconsin.
Other physician assistant in Racine
- Sara HollandMadison$189K
- Lisa SershonMilwaukee$182K
- Sarah VicariFranklin$120K
- Jessica SzpakBaraboo$95K
- Amy BurmeschMenomonee Falls$79K
- Eric GoddeyneGreen Bay$61K
- Charnai SherryMilwaukee$45K
- Victoria MaloneyWauwatosa$28K
- Joseph FraneckiMilwaukee$27K
- Amanda SellFranklin$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.